Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
701 (USA) · Dr. Reyes
consented 2013-02-12
Adverse events
Moderate APPLICATION SITE ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-03-19 (study day 36.0); relationship: POSSIBLE
Moderate APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-03-19 (study day 36.0); relationship: POSSIBLE
Moderate APPLICATION SITE VESICLES — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-03-19 (study day 36.0); relationship: POSSIBLE
Moderate HEADACHE — outcome: NOT RECOVERED/NOT RESOLVED; onset 2002; relationship: NONE
Mild MICTURITION URGENCY — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-02-15 (study day 4.0); relationship: POSSIBLE
Mild MICTURITION URGENCY — outcome: RECOVERED/RESOLVED; onset 2013-02-15 (study day 4.0); relationship: POSSIBLE
Mild NASOPHARYNGITIS — outcome: RECOVERED/RESOLVED; onset 2013-03-06 (study day 23.0); relationship: NONE
Mild VOMITING — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-02-12 (study day 1.0); relationship: NONE
Mild VOMITING — outcome: RECOVERED/RESOLVED; onset 2013-02-12 (study day 1.0); relationship: NONE
Data queries
No data queries.